The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
- Author
- PIGNOCHINO, Ymera1 2 ; DELL'AGLIO, Carmine1 2 ; D'AMBROSIO, Lorenzo1 2 ; FAGIOLI, Franca7 ; FERRARI, Stefano8 ; ALBERGHINI, Marco8 ; PICCI, Piero8 ; AGLIETTA, Massimo2 9 ; GRIGNANI, Giovanni1 ; BASIRICO, Marco1 2 ; CAPOZZI, Federica1 2 ; SOSTER, Marco3 ; MARCHIO, Serena3 ; BRUNO, Stefania4 ; GAMMAITONI, Loretta5 ; SANGIOLO, Dario2 5 ; TORCHIARO, Erica2 6
[1] Sarcoma Group, Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy
[2] Department of Oncology, University of Torino Medical School, Italy
[3] Tumor Microenvironment, Fondazione Piemontese per la Ricerca sul Cancro-ONLUS, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy
[4] Department of Internal Medicine, University of Torino, Molecular Biotechnology Center and Center of Experimental Research and Medical Sciences, Torino, Italy
[5] Cell Therapy, Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy
[6] Cancer Genetics, Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy
[7] Division of Pediatric Onco-Hematology, Sant'Anna OIRM Hospital, Torino, Italy
[8] Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
[9] Medical Oncology, Fondazione del Piemonte per ÍOncologia, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy - Source
Clinical cancer research (Print). 2013, Vol 19, Num 8, pp 2117-2131, 15 p ; ref : 37 ref
- CODEN
- CCREF4
- ISSN
- 1078-0432
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Antiangiogénique Anticancéreux Essai préclinique Evérolimus Modèle Os Ostéosarcome Sarcome Sorafénib Complexe mTORC1 Inhibiteur mTOR Cancer Inhibiteur de la tyrosine kinase Inhibiteur enzyme Inhibiteur multikinase Inhibiteur synthèse protéique Lactone Macrolide Pathologie du système ostéoarticulaire Système ostéoarticulaire Tumeur maligne
- Keyword (en)
- Antiangiogenic agent Antineoplastic agent Preclinical trial Everolimus Models Bone Osteosarcoma Sarcoma Sorafenib Cancer Tyrosine kinase inhibitor Enzyme inhibitor Multikinase inhibitor Protein synthesis inhibitor Lactone Macrolide Diseases of the osteoarticular system Osteoarticular system Malignant tumor
- Keyword (es)
- Antiangiogenico Anticanceroso Ensayo preclínico Everolimus Modelo Hueso Osteosarcoma Sarcoma Sorafenib Cáncer Inhibidor tyrosine kinase Inhibidor enzima inhibidor multicinasa Inhibidor síntesis proteica Lactona Macrólido Sistema osteoarticular patología Sistema osteoarticular Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B15 Diseases of the osteoarticular system / 002B15C Tumors of striated muscle and skeleton
- Discipline
- Osteoarticular pathology Pharmacological treatments Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27382871
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1158/1078-0432.CCR-12-2293 
https://dx.doi.org/10.1158/1078-0432.CCR-12-2293
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-12-2293\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"2117\";s:8:\"\u0000*\u0000epage\";s:4:\"2131\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"PIGNOCHINO\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Ymera\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:19:\"DELL'AGLIO, Carmine\";i:1;s:19:\"D'AMBROSIO, Lorenzo\";i:2;s:15:\"FAGIOLI, Franca\";i:3;s:16:\"FERRARI, Stefano\";i:4;s:17:\"ALBERGHINI, Marco\";i:5;s:12:\"PICCI, Piero\";i:6;s:17:\"AGLIETTA, Massimo\";i:7;s:18:\"GRIGNANI, Giovanni\";i:8;s:15:\"BASIRICO, Marco\";i:9;s:17:\"CAPOZZI, Federica\";i:10;s:13:\"SOSTER, Marco\";i:11;s:15:\"MARCHIO, Serena\";i:12;s:15:\"BRUNO, Stefania\";i:13;s:19:\"GAMMAITONI, Loretta\";i:14;s:15:\"SANGIOLO, Dario\";i:15;s:16:\"TORCHIARO, Erica\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"15\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-12-2293\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"2117\";s:8:\"\u0000*\u0000epage\";s:4:\"2131\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"PIGNOCHINO\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Ymera\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:19:\"DELL'AGLIO, Carmine\";i:1;s:19:\"D'AMBROSIO, Lorenzo\";i:2;s:15:\"FAGIOLI, Franca\";i:3;s:16:\"FERRARI, Stefano\";i:4;s:17:\"ALBERGHINI, Marco\";i:5;s:12:\"PICCI, Piero\";i:6;s:17:\"AGLIETTA, Massimo\";i:7;s:18:\"GRIGNANI, Giovanni\";i:8;s:15:\"BASIRICO, Marco\";i:9;s:17:\"CAPOZZI, Federica\";i:10;s:13:\"SOSTER, Marco\";i:11;s:15:\"MARCHIO, Serena\";i:12;s:15:\"BRUNO, Stefania\";i:13;s:19:\"GAMMAITONI, Loretta\";i:14;s:15:\"SANGIOLO, Dario\";i:15;s:16:\"TORCHIARO, Erica\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"15\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-12-2293\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-12-2293\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"2117\";s:8:\"\u0000*\u0000epage\";s:4:\"2131\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"PIGNOCHINO\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Ymera\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:19:\"DELL'AGLIO, Carmine\";i:1;s:19:\"D'AMBROSIO, Lorenzo\";i:2;s:15:\"FAGIOLI, Franca\";i:3;s:16:\"FERRARI, Stefano\";i:4;s:17:\"ALBERGHINI, Marco\";i:5;s:12:\"PICCI, Piero\";i:6;s:17:\"AGLIETTA, Massimo\";i:7;s:18:\"GRIGNANI, Giovanni\";i:8;s:15:\"BASIRICO, Marco\";i:9;s:17:\"CAPOZZI, Federica\";i:10;s:13:\"SOSTER, Marco\";i:11;s:15:\"MARCHIO, Serena\";i:12;s:15:\"BRUNO, Stefania\";i:13;s:19:\"GAMMAITONI, Loretta\";i:14;s:15:\"SANGIOLO, Dario\";i:15;s:16:\"TORCHIARO, Erica\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"15\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/1078-0432.CCR-12-2293\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Clinical cancer research (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Clin. cancer res. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"2117\";s:8:\"\u0000*\u0000epage\";s:4:\"2131\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1078-0432\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"PIGNOCHINO\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Ymera\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:19:\"DELL'AGLIO, Carmine\";i:1;s:19:\"D'AMBROSIO, Lorenzo\";i:2;s:15:\"FAGIOLI, Franca\";i:3;s:16:\"FERRARI, Stefano\";i:4;s:17:\"ALBERGHINI, Marco\";i:5;s:12:\"PICCI, Piero\";i:6;s:17:\"AGLIETTA, Massimo\";i:7;s:18:\"GRIGNANI, Giovanni\";i:8;s:15:\"BASIRICO, Marco\";i:9;s:17:\"CAPOZZI, Federica\";i:10;s:13:\"SOSTER, Marco\";i:11;s:15:\"MARCHIO, Serena\";i:12;s:15:\"BRUNO, Stefania\";i:13;s:19:\"GAMMAITONI, Loretta\";i:14;s:15:\"SANGIOLO, Dario\";i:15;s:16:\"TORCHIARO, Erica\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCREF4\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"15\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
